| 中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
|---|---|---|---|---|
| —— | 2-(benzoyloxymethyl)-6-chloro-9-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythro-furanosyl)purine | 917235-49-5 | C34H29ClN4O7 | 641.08 |
| 2,6-二氯-9-(3,5-二-O-对甲苯甲酰基-2-脱氧-beta-D-赤式-呋喃戊糖基)嘌呤 | 2,6-Dichloro-9-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythro-pentofuranosyl)-purine | 38925-80-3 | C26H22Cl2N4O5 | 541.39 |
| —— | 6-chloro-2-iodo-9-[2’-deoxy-3’,5’-di-O-(4-methylbenzoyl)-β-D-ribofuranosyl]purine | 118706-48-2 | C26H22ClIN4O5 | 632.842 |
An efficient methodology of the synthesis of 6-substituted 2-(hydroxymethyl)purine derivatives (bases and nucleosides) was developed. Regioselective Pd-catalyzed cross-coupling reactions of 6-chloro-2-iodopurines with [(benzoyloxy)methyl]zinc iodide gave 2-[(benzoyloxy)-methyl]-6-chloropurines that were converted to 2-(hydroxymethyl)adenines by reactions with ammonia and to 6-methyl- or 6-aryl-2-(hydroxymethyl)purines by cross-coupling reactions with trimethylaluminium or arylboronic acids followed by deprotection. The title 6-substituted 2-(hydroxymethyl)purine bases and nucleosides did not exhibit significant cytostatic or anti-HCV activity.